The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20141632: The Providence Service Corporation; Welsh, Carson Anderson & Stowe XI, L.P.
20141634: Patterson-UTI Energy, Inc.; Platinum Energy Holdings, Inc.
20141641: AppNexus Inc.; WPP plc
20141622: AEA Investors Fund V LP; The Resolute Fund II, L.P.
1409005 Informal Interpretation
Advertising Allowances and Other Merchandising Payments and Services ("Fred Meyer Guides")
1409004 Informal Interpretation
20141603: EnerVest Energy Institutional Fund XIII-C, L.P.; Loews Corporation
20141605: Sentinel Capital Partners V, L.P.; Huntsman Gay Capital Partners Fund, L.P.
L'Oreal USA, In the Matter of
Pinnacle Payment Services, LLC
Federal Trade Commission Comment Before the Federal Communications Commission Regarding the Privacy and Security Practices of Broadband Providers and Their Impact On Broadband Adoption
20141556: 3i Group plc; Audax Private Equity Fund II, L.P.
Akorn, Inc., In the Matter of
Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive. According to the FTC’s complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin and there are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC’s proposed settlement with Akorn requires the company to divest its Abbreviated New Drug Application for generic injectable rifampin – which is currently pending before the Food and Drug Administration – to Watson Laboratories, Inc.